Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 5/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.48 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CFD | P00746 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22971683 | 0.93 | PHGDH (0.51) | ROCK1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL21241826 | 0.89 | ROCK1 (0.49) | ROCK1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL22971654 | 0.89 | ABL1 (0.55) | ROCK1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL22971635 | 0.89 | ROCK1 (0.56) | ROCK1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL21241936 | 0.89 | HDAC3 (0.50) | ROCK1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL21242059 | 0.88 | HDAC3 (0.46) | ROCK1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL22971555 | 0.88 | HDAC3 (0.48) | ROCK1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL22971678 | 0.88 | HDAC3 (0.49) | ROCK1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL22971735 | 0.88 | HDAC1 (0.56) | ROCK1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL21241972 | 0.88 | WNT3A (0.53) | ROCK1ROCK2PRKACACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20210038611-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2021-02-11 | — | — | US | disclosed |
| WO-2019152437-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | ROCK1 4248/4885HDAC3 231/4885HDAC1 242/4885 |
| US-20210038611-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | ROCK1 4248/4885HDAC3 231/4885HDAC1 242/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | ROCK1 1283/4885HDAC3 563/4885HDAC1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.